Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celltrion To Cancel 3.99 Percent Of Its Shares To Add Value For Shareholders

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korean biotech Celltrion plans to cancel 3.99 percent or 4.812 million shares to add more value to its shares following a capital expansion in April by Singapore's Ion Investments B.V., a wholly owned subsidiary of Temasek Holdings. The move was approved by Celltrion's board June 21

You may also be interested in...



Korean Court Upholds Employee Non-competition Clause In LG Contract; Puts Brakes On Samsung's Manhunt For Biosimilar Specialists

SEOUL - A Seoul district court has derailed, for the time being, Samsung Electronics' efforts to snatch up biosimilars experts from competitors including LG Life Sciences

Samsung Group Set To Enter Biosimilars Market With $1.9 Billion Investment

SEOUL - Samsung Group has ended years of exploration for new business realms beyond its traditional pipeline of semiconductors and electronics products; South Korea's leading conglomerate is set to enter the healthcare sector, particularly biosimilars and medical devices, with an initial investment of roughly $4.1 billion

Korea's Celltrion Sells 10 Percent Of Its Shares To Singapore's Temasek To Fund Biosimilar Development

SEOUL - South Korean biotech Celltrion plans on speeding up development of its biosimilars by selling a 10 percent stake in the company to Singapore's Ion Investments B.V., a wholly-owned subsidiary of Temasek Holdings

UsernamePublicRestriction

Register

OM013133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel